• ViiV builds case for long-acting HIV doublet firstwordpharma
    March 15, 2019
    Gilead Sciences has maintained its dominant position in the HIV marketplace thanks to a new generation of safer triplet drugs but ViiV Healthcare revealed more Phase III results suggesting that a long-acting injectable doublet may be able to elbow out a s
PharmaSources Customer Service